These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12875732)

  • 1. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment.
    Jia H; Du J; Zhu S; Ma Y; Cai H
    Chin Med J (Engl); 2003 Apr; 116(4):605-8. PubMed ID: 12875732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C.
    Jia HY; Du J; Zhu SH; Ma YJ; Chen HY; Yang BS; Cai HF
    Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):378-82. PubMed ID: 14607710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
    Abe S; Narita R; Matsuhashi T; Oto T; Tabaru A; Otsuki M
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):373-8. PubMed ID: 18403937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
    Grüngreiff K; Reinhold D; Ansorge S
    Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
    Kitaoka S; Shiota G; Kawasaki H
    Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
    Zhang L; Hao CQ; Miao L; Dou XG
    Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
    Simsek H; Kadayifci A
    J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
    Naveau S; Balian A; Degos F; Daurat V; Chevret S; Gayno S; Bastie A; Riachi G; Bartolomei-Portal I; Barange K; Moussalli J; Bailly F; Chaumet-Riffaud P; Emilie D
    J Hepatol; 1999 Oct; 31(4):612-7. PubMed ID: 10551383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
    Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
    Gur A; Dikici B; Nas K; Bosnak M; Haspolat K; Sarac AJ
    BMC Gastroenterol; 2005 Sep; 5():30. PubMed ID: 16171525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection.
    Kawakami Y; Nabeshima S; Furusyo N; Sawayama Y; Hayashi J; Kashiwagi S
    Am J Gastroenterol; 2000 Jan; 95(1):227-32. PubMed ID: 10638589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
    Zekri AR; Haleem HA; Esmat GE; Bahnassy AA; El-Din HM; Hafez MM; Sharaby AF; Sharaf H; Zakaria MS
    J Viral Hepat; 2007 Jul; 14(7):468-77. PubMed ID: 17576388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.
    Sawayama Y; Hayashi J; Kawakami Y; Furusyo N; Ariyama I; Kishihara Y; Ueno K; Kashiwagi S
    Dig Dis Sci; 1999 Jan; 44(1):163-9. PubMed ID: 9952238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immune-regulating Th1- and Th2-cytokines in chronic infections caused by hepatitis B and C viruses].
    Priĭmiagi LS; Tefanova VT; Tallo TG; Shmidt EV; Solomonova OV; Tuĭsk TP
    Vopr Virusol; 2003; 48(4):37-40. PubMed ID: 12945206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
    Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
    Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Schistosoma mansoni co-infection on serum profile of interferon-gamma, interleukin-4 and interleukin-10 in patients with chronic hepatitis C virus infection.
    Emam EA; Emam M; Shehata AE; Emara M
    Egypt J Immunol; 2006; 13(2):33-40. PubMed ID: 18689269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.
    Wang J; Xiang GJ; Liu BX
    World J Gastroenterol; 2003 Apr; 9(4):751-4. PubMed ID: 12679925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
    Farrell GC; Bacon BR; Goldin RD
    Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum cytokine profiles in patients with adult onset Still's disease.
    Choi JH; Suh CH; Lee YM; Suh YJ; Lee SK; Kim SS; Nahm DH; Park HS
    J Rheumatol; 2003 Nov; 30(11):2422-7. PubMed ID: 14677188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
    Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
    Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.